Theerut Luangmonkong1,2, Su Suriguga1, Emilia Bigaeva1, Miriam Boersema1, Dorenda Oosterhuis1, Koert P de Jong3, Detlef Schuppan4,5, Henricus A M Mutsaers1, Peter Olinga1. 1. Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, The Netherlands. 2. Department of Pharmacology, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand. 3. Department of Hepato-Pancreato-Biliary Surgery and Liver Transplantation, University Medical Center Groningen, University of Groningen, The Netherlands. 4. Institute of Translational Immunology and Research Center for Immunotherapy, University of Mainz Medical Center, Mainz, Germany. 5. Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Abstract
BACKGROUND AND PURPOSE: Liver fibrosis is a major cause of liver-related mortality and, so far, no effective antifibrotic drug is available. Galunisertib, a TGF-β receptor type I kinase inhibitor, is a potential candidate for the treatment of liver fibrosis. Here, we evaluated the potency of galunisertib in a human ex vivo model of liver fibrosis. EXPERIMENTAL APPROACH: Antifibrotic potency and associated mechanisms were studied ex vivo, using both healthy and cirrhotic human precision-cut liver slices. Fibrosis-related parameters, both transcriptional and translational level, were assessed after treatment with galunisertib. KEY RESULTS: Galunisertib showed a prominent antifibrotic potency. Phosphorylation of SMAD2 was inhibited, while that of SMAD1 remained unchanged. In healthy and cirrhotic human livers, spontaneous transcription of numerous genes encoding collagens, including collagen type I, α 1, collagen maturation, non-collageneous extracellular matrix (ECM) components, ECM remodelling and selected ECM receptors was significantly decreased. The reduction of fibrosis-related transcription was paralleled by a significant inhibition of procollagen I C-peptide released by both healthy and cirrhotic human liver slices. Moreover, galunisertib showed similar antifibrotic potency in human and rat lives. CONCLUSIONS AND IMPLICATIONS: Galunisertib is a drug that deserves to be further investigated for the treatment of liver fibrosis. Inhibition of SMAD2 phosphorylation is probably a central mechanism of action. In addition, blocking the production and maturation of collagens and promoting their degradation are related to the antifibrotic action of galunisertib.
BACKGROUND AND PURPOSE:Liver fibrosis is a major cause of liver-related mortality and, so far, no effective antifibrotic drug is available. Galunisertib, a TGF-β receptor type I kinase inhibitor, is a potential candidate for the treatment of liver fibrosis. Here, we evaluated the potency of galunisertib in a human ex vivo model of liver fibrosis. EXPERIMENTAL APPROACH: Antifibrotic potency and associated mechanisms were studied ex vivo, using both healthy and cirrhotic human precision-cut liver slices. Fibrosis-related parameters, both transcriptional and translational level, were assessed after treatment with galunisertib. KEY RESULTS:Galunisertib showed a prominent antifibrotic potency. Phosphorylation of SMAD2 was inhibited, while that of SMAD1 remained unchanged. In healthy and cirrhotic human livers, spontaneous transcription of numerous genes encoding collagens, including collagen type I, α 1, collagen maturation, non-collageneous extracellular matrix (ECM) components, ECM remodelling and selected ECM receptors was significantly decreased. The reduction of fibrosis-related transcription was paralleled by a significant inhibition of procollagen I C-peptide released by both healthy and cirrhotic human liver slices. Moreover, galunisertib showed similar antifibrotic potency in human and rat lives. CONCLUSIONS AND IMPLICATIONS: Galunisertib is a drug that deserves to be further investigated for the treatment of liver fibrosis. Inhibition of SMAD2 phosphorylation is probably a central mechanism of action. In addition, blocking the production and maturation of collagens and promoting their degradation are related to the antifibrotic action of galunisertib.
Authors: Kyle E Brown; Kimberly A Broadhurst; M Meleah Mathahs; Elizabeth M Brunt; Warren N Schmidt Journal: Lab Invest Date: 2005-06 Impact factor: 5.662
Authors: Eliza Wiercinska; Lucia Wickert; Bernd Denecke; Harun M Said; Jafar Hamzavi; A M Gressner; Midori Thorikay; Peter ten Dijke; Peter R Mertens; Katja Breitkopf; Steven Dooley Journal: Hepatology Date: 2006-05 Impact factor: 17.425
Authors: Elisabeth G D Stribos; Theerut Luangmonkong; Anna M Leliveld; Igle J de Jong; Willem J van Son; Jan-Luuk Hillebrands; Marc A Seelen; Harry van Goor; Peter Olinga; Henricus A M Mutsaers Journal: Transl Res Date: 2015-11-25 Impact factor: 7.012
Authors: Stephen Ph Alexander; Doriano Fabbro; Eamonn Kelly; Neil Marrion; John A Peters; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Christopher Southan; Jamie A Davies Journal: Br J Pharmacol Date: 2015-12 Impact factor: 8.739
Authors: Si Cao; Baoping Zheng; Tao Chen; Xinfeng Chang; Bao Yin; Zhihua Huang; Ping Shuai; Limin Han Journal: Drug Des Devel Ther Date: 2018-05-11 Impact factor: 4.319
Authors: Shan Yu; Matthew Ericson; Andrea Fanjul; Derek M Erion; Maria Paraskevopoulou; Erin N Smith; Banumathi Cole; Ryan Feaver; Corine Holub; Narender Gavva; Shane R Horman; Jie Huang Journal: ACS Chem Biol Date: 2022-03-11 Impact factor: 4.634